Literature DB >> 3280842

The FDA's new procedures for the use of investigational drugs in treatment.

F E Young1, J A Norris, J A Levitt, S L Nightingale.   

Abstract

The Food and Drug Administration has established new procedures to make promising investigational drugs available for treatment of patients with immediately life-threatening or serious diseases as early in the drug development process as possible and well before general marketing begins. The purpose of this article is to inform the medical community about these new procedures and to facilitate their implementation. Examples of immediately life-threatening and serious diseases are given and the procedures that physicians should use to obtain a drug under the new regulations are described. The treatment use of zidovudine (Retrovir), while still in the investigational phase, is described as a case study. The article also summarizes the Food and Drug Administration's new procedures under which drug sponsors can charge for investigational drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280842

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

Review 1.  Ethical problems raised by anti-HIV vaccination.

Authors:  P Enel; J Charrel; M P Larher; D Reviron; C Manuel; J L San Marco
Journal:  Eur J Epidemiol       Date:  1991-03       Impact factor: 8.082

Review 2.  Investigational drugs for treatment use: an avenue of hope for minority populations.

Authors:  R V Veiga; C A Reid
Journal:  J Natl Med Assoc       Date:  1989-05       Impact factor: 1.798

Review 3.  Advances in clinical trials for amyotrophic lateral sclerosis.

Authors:  Paul H Gordon
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

4.  New FDA drug approval policies and HIV vaccine development.

Authors:  W K Mariner
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

5.  The ethical approach to AIDS: a bibliographical review.

Authors:  C Manuel; P Enel; J Charrel; D Reviron; M P Larher; X Thirion; J L Sanmarco
Journal:  J Med Ethics       Date:  1990-03       Impact factor: 2.903

6.  Ethics in the Time of Coronavirus: Recommendations in the COVID-19 Pandemic.

Authors:  Jessica B Kramer; Douglas E Brown; Piroska K Kopar
Journal:  J Am Coll Surg       Date:  2020-04-09       Impact factor: 6.113

7.  Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.

Authors:  Tobias B Polak; Joost van Rosmalen; Carin A Uyl-de Groot
Journal:  Br J Clin Pharmacol       Date:  2020-04-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.